New Pilot Study Finds Cosamin® ASU Effective in Reducing Concentrations of Key Biomarkers Associated with Joint Discomfort and Cartilage Breakdown

EDGEWOOD, Md., Feb. 29, 2016 /PRNewswire/ -- Nutramax Laboratories Consumer Care, Inc. today announced the results of a six-week, open-label pilot study that found Cosamin^®ASU, the company's advanced joint health formulation, is effective in reducing concentrations of serum and urine biomarkers associated with joint discomfort and cartilage breakdown. The study, carried out by researchers at the University of Missouri, also included clinical assessments which found that Cosamin ASU may be associated with improvements in measures of function and quality of life.

"This is the first study to show that serum and urine biomarkers can effectively detect improvements in a comprehensive spectrum of validated clinical outcome measures of pain, function and quality of life in patients receiving Cosamin ASU," said Dr. James Cook, principle study investigator and Director, University of Missouri Comparative Orthopaedic Laboratory, Mizzou BioJoint Center.

Cosamin ASU is a combination of glucosamine hydrochloride (FCHG49^®), chondroitin sulfate (TRH122^®), avocado/soybean unsaponifiables (NMX1000^® ASU), 3-O-acetyl-11-keto-boswellic acid (AKBA) (QUIKLOX™), and decaffeinated green tea extract.

Throughout the study period, investigators collected, processed and analyzed blood and urine from five patients using a multiplexed proprietary panel of biomarkers. At each of the five clinic visits throughout the trial, SF-36, KOOS, WOMAC, and IKDC subject and exam questionnaires were administered according to published protocols.

All serum and urine biomarkers evaluated showed measured changes in concentrations over the study period with statistically significant (p<0.05) differences noted for serum PGE2, MMP1, GRO, IL8, and high-sensitivity C-reactive protein (hsCRP) and urine PGE2, MMP2, MMP3, GRO and IL8; markers associated with joint discomfort and cartilage breakdown.

"This comprehensive pilot analysis provides us with additional support of the efficacy of Cosamin ASU for promoting joint health," said Dr. Brian Cornblatt, Medical Director of Nutramax Laboratories Consumer Care, Inc. "Using biomarkers to assess our products in the human clinical trial setting allows us to translate our in vitro findings. For years we have studied the effects of our novel formulations on well-recognized tissue culture models. To see these same biomarkers associated with joint discomfort and cartilage breakdown decrease significantly in a clinical trial setting is reassuring as we carefully seek to develop our products backed by sound and robust science."

Subsequent research plans include a multi-center, placebo-controlled clinical study aimed at further bridging clinical assessments of Cosamin ASU with validated biomarkers.

About the Nutramax Laboratories Family of Companies:

Since 1992, Christian-based Nutramax Laboratories has been developing products for people and their pets. Nutramax Laboratories Consumer Care, Inc., located in Edgewood, Maryland, focuses on researching and developing high quality products to promote consumer health. Located in Lancaster, South Carolina, Nutramax Laboratories Veterinary Sciences, Inc. researches and develops high quality products to support animal health. Nutramax Manufacturing, Inc. manufactures products in both the Maryland and South Carolina locations.

Cosamin^® joint health supplements, including the original Cosamin^®DS and advanced formula Cosamin^®ASU, are available at retailers across the U.S. to help support and promote joint health.

SOURCE Nutramax Laboratories Consumer Care, Inc.

Related Links

http://www.nutramaxlabs.com/your-health